ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AbbVie and Genmab sign oncology antibody pact

by Michael McCoy
June 13, 2020 | APPEARED IN VOLUME 98, ISSUE 23

 

AbbVie will pay the Danish antibody specialist Genmab $750 million as part of a deal to commercialize three of Genmab’s biospecific antibodies for cancer. Genmab could get another $3.2 billion in milestone payments. The pact joins Genmab antibodies, which can direct cytotoxic T cells to tumors, with AbbVie’s antibody-drug conjugate technology. Genmab already has threecommercialized antibodies under its belt through partnerships with Janssen, Novartis, and Roche.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment